

**Editorial**

Cathy Kroll, Swiss Biotech Association



We look back on a very successful Swiss Biotech Day 2018 in Basel and forward to the next Swiss Biotech Day Fall on 27 September 2018 in Lausanne. NTN Swiss Biotech has compiled valuable information that demonstrates the power and potential of Swiss Biotech: The Swiss Biotech Report.

Enjoy the reading!

**Facts and figures from the Swiss Biotech Report**



The success of the Swiss biotech industry continues. In 2017, the 237 biotech companies and 60 suppliers of the industry employed more than 13,700 staff members (+2.5%) and their sales increased by 14% to reach CHF 3.79 bn. Compared to the previous year, capital investment in private and listed Swiss biotech companies doubled to CHF 1.64 bn – the highest figure since the Swiss Biotech report was first published. In addition, investment in research and development increased by more than 22% to CHF 1.39 bn. The value of pharmaceutical and biotechnology product exports in 2017 totaled CHF 83.8 bn, which is about 38% of the total Swiss export volume.

Download: [www.swissbiotechreport.ch](http://www.swissbiotechreport.ch)


**New records at the Swiss Biotech Day**

More than 600 senior executives of the life science industry across Europe visited the Swiss Biotech Day in Basel – a record-breaking attendance. Record figures were also revealed for the Swiss biotech industry for 2017 in financing, infrastructure investment, and exports. Further highlights of the day included the keynote from Novartis CEO, Vas Narasimhan, and the launch of the Swiss Biotech Success Stories for remarkable industry achievements.



The future for Swiss biotech looks very promising: The solid development pipeline of the industry and the quality of its patents will secure Swiss biotechnology's place on the global market in the longer term.

At the annual get-together of the industry, sessions on fostering closer cooperation between companies and investors, partnering talks in a private setting, discussions with experts on financing, as well as presentations of more than a dozen young companies and start-ups, awaited the participants. On the occasion of its 20th anniversary, the Swiss Biotech Association launched its new campaign, the Swiss Biotech Success Stories, in the evening. The first recognitions, selected by an independent jury of experts, went to Biogen, Roche Glycart, Okairo, Selexis and Vifor Fresenius Medical Care Renal Pharma. In the future, more Swiss Biotech Success Stories will be added to cover all of the industry's different facets. "Biotech is one of the most innovative sectors in Switzerland. The industry represents an unparalleled success story, attracting talents and investments from all around the globe", said Michael Altorfer, CEO of the Swiss Biotech Association. "With Swiss Biotech Success Stories we are honoring our pioneers, entrepreneurs, innovators, and leaders – all those extraordinary people who lead the way, open the horizon, and prepare the ground for lasting achievements."



Swiss export statistics by industry show that the chemical, pharmaceutical and biotech industries are growing rapidly and already contribute more than 40% to the Swiss exports. Source: scienceindustries, Swiss Biotech Report 2018

NTN partners:




**Contents**


- Facts and figures from the Swiss Biotech Report
- Swiss Biotech Day

**The number of Swiss biotech companies is growing steadily.**

This chart by EY from the Swiss Biotech Report 2018 only shows the number of companies developing new therapies. Overall, the Swiss biotech industry has grown by more than 50% in the last 10 years and comprises a total of around 800 companies, including the numerous companies that provide services for patent protection, research, clinical studies or in the fields of analytics, diagnostics or production.




**Swiss Biotech Day:** A packed program for the life science industry with plenty of room for networking



**Swiss biotech: Record figures in infrastructure investments 2017**

The continuous and large investments in infrastructure for e.g. mammalian cell production as shown here indicate a long-term commitment of national and international biotech companies. The need for qualified staff for biotech will be an ongoing critical success factor for the Swiss biotech industry.



**Contact:**

**NTN-SwissBiotech**  
 Editor C. Kroll - [kroll@swissbiotech.org](mailto:kroll@swissbiotech.org)  
 Advertising H. Bihlman - [bihlman@swissbiotech.org](mailto:bihlman@swissbiotech.org)  
 Published 2-3 times a year (print or pdf)

**Main Office, Zürich**  
 Swiss Biotech Association  
 Stauffacherstrasse 16  
 8004 Zürich

**Office Romandie**  
 Swiss Biotech Association  
 Rue Haldimand 15  
 1003 Lausanne